Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells

Launched by VANDERBILT UNIVERSITY MEDICAL CENTER · Apr 8, 2025

Keywords

ClinConnect Summary

This clinical trial is designed to investigate how immune cells in our body use glucose, a common sugar, to create energy and support their functions. Researchers will give participants a special type of glucose through an IV (intravenous) infusion. This glucose is not radioactive and will help the team track how immune cells take in and use it over a few hours. By studying this process, the researchers hope to learn more about how our immune system works, especially in relation to diseases that affect glucose metabolism.

To be eligible for this study, participants need to be adults aged 18 or older. However, there are some individuals who cannot participate, such as pregnant women, those with poorly controlled diabetes, or anyone involved in another study that requires too much blood to be drawn. Participants can expect to have some blood drawn during the trial to collect immune cells, but the process is designed to be safe and well-managed. It's important to know that the study is not currently recruiting participants, but it will be open to people of all genders when it begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults aged 18 or older
• Exclusion Criteria:
• • Pregnant
• • Prisoner or in police custody
• • Uncontrolled hyperglycemia/diabetes
• • Current participation in another study where the total volume of blood drawn, when added to this study blood draw volume, exceeds 500cc in an 8 week period
• • Any medical issue or pharmacologic exposure which, in the opinion of the study investigator, that might interfere with the study objectives
• • Any reason which, in the opinion of the study investigator, adds additional risk to the participant